Furthermore, Younossi et al. proposed Helz2, a transcriptional co-regulator involved in hepatic lipid metabolism, as a promising molecular target [42]. At the preclinical level, hepatic steatosis was ameliorated and insulin sensitivity enhanced by pharmacologic Helz2 blockade by guanabenz acetate. This evidence concerns the gene HELZ2 and Hepatic steatosis.